Braveheart Bio (NASDAQ:BRVE) Director Buys $74,988.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Malek purchased 4,166 shares of the stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $74,988.00. Following the completion of the acquisition, the director directly owned 533,845 shares in the company, valued at approximately $9,609,210. This trade represents a 0.79% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Braveheart Bio Stock Performance

Shares of BRVE stock traded up $0.20 on Friday, reaching $30.00. The stock had a trading volume of 566,417 shares. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00.

Braveheart Bio Company Profile

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.